Compare Neurocrine Biosciences Inc (NBIX) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Financial Select Sector SPDR Fund — how do they compare? Neurocrine Biosciences Inc trades at $141.13 (market cap $14.36B), while Financial Select Sector SPDR Fund trades at $54.43 (market cap $50.06B). The key difference: Financial Select Sector SPDR Fund is far larger — about 3.5× Neurocrine Biosciences Inc's market cap, and Financial Select Sector SPDR Fund is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| NBIX | XLF | |
|---|---|---|
Market Cap | $14.36B | $50.06B |
Volume | 1,237,180 | 47,464,120 |
Sector | Health | — |
52-Week High | $185.50 | $58.55 |
52-Week Low | $123.10 | $47.80 |
Typical Hold Time | 23 Days | 104 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
XLF trades at $53.75, down 0.48% with bearish technical signals from moving averages. The financial sector faces headwinds as bank stocks lag the S&P 500 by the widest margin since 1990 despite rising profits. Recent Fed stress test changes and interest rate hikes create a mixed environment for financial institutions, with higher rates potentially benefiting some sector components while increasing borrowing costs.
The ETF's concentrated exposure to 76 large-cap financial firms positions it for potential gains from rising rates, though sector underperformance and regulatory uncertainty present near-term challenges. Fund managers increased financial allocations in Q2 2026, suggesting institutional confidence in the sector's rate sensitivity advantages over tech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
